Careers  |  Sign In  |  Register  |   Twitter
HCV CME Banner
Series Progress
Part 1
Part 2
Part 3
Part 4

Part 1

The Evolution of SOC in HCV

What Have we Learned about Starting Therapy Today?

Sponsorship Statement

This continuing medical education activity is sponsored by

Vindico Medical Education

Support Statement

This activity is supported by an educational grant from

Genentech

Target Audience

The intended audience for the activities is hepatologists, gastroenterologists, infectious disease specialists, nurse practitioners, physician assistants and other healthcare professionals involved in the treatment of patients with hepatitis C.

Learning Objectives

At the conclusion of this activity participants should be able to:

  • Evaluate critical issues and apply evidence-based approaches for current triple-therapy regimens, including treatment selection, initiation, and duration of therapy.
  • Discuss HCV treatment and management strategies that address adverse events (AEs), drug-drug interactions (DDIs), and issues relating to drug adherence.
  • Assess the use and limitations of triple therapy in specific patient populations such patients with cirrhosis, transplant recipients, and patients who are coinfected with HIV.
  • Examine clinical data about the safety and efficacy of investigational HCV treatments and the risk-benefits of treating now versus waiting.

Overview

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. Effective management of HCV continues to pose a challenge for healthcare practitioners. The discovery, development, and availability of direct-acting antiviral agents (DAAs) offers new treatment options and the possibility of improved outcomes for newly diagnosed patients as well as those who have experienced a relapse or failed to respond to previous treatment. However, their use introduces new challenges and adds to the complexity of HCV treatment and care. With rapid advancements in the field and new agents offering potential improvements in outcomes, shorter treatment durations, and unique adverse event profiles, clinicians must stay informed of the evolving data in order to counsel patients appropriately—in particular, those who may wish to discuss the benefits and risks of initiating therapy now vs delaying treatment. This program will consist of a series of four video vignettes presenting interviews with clinical experts who will explore some of the most pressing issues in the management of patients with HCV.

Course Chair

Donald M. Jensen, MD, FACP
Director, Center for Liver Diseases
University of Chicago Medical Center
Chicago, IL

Faculty

Paul Pockros, MD
Head, Division of Gastroenterology and Hepatology
Director, Center for Liver Diseases Scripps Clinic
Director, SC Liver Research Consortium
La Jolla, CA

David R. Nelson, MD
Professor of Medicine, Molecular Genetics and Microbiology
Director, UF Clinical and Translational Science Institute
Associate Dean for Clinical Research
Division of Gastroenterology, Hepatology, and Nutrition
Gainesville, FL

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release: June 28, 2013 to June 28, 2014.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, complete the CME posttest, and complete the and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.

Planning Committee and Faculty

Donald M. Jensen, MD, FACP
David R. Nelson, MD
Paul Pockros, MD

External Reviewer

Craig Aronchick, MD

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

  • Planning Committee and Faculty members report the following relationship(s):
    • Donald M. Jensen, MD, FACP
      • Consulting Fees: Abbott, Astex, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Janssen, Merck, Vertex
      • Contracted Research: Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Janssen, Vertex
      • Other: Consensus Medical Communications, Clinical Care Options
    • David R. Nelson, MD
      • Contracted Research: Abbott, Bristol-Myers Squibb, Gilead, Merck, Vertex
    • Paul Pockros, MD
      • Consulting Fees: Vertex, Merck, Gilead, Bristol-Myers Squibb, Janssen
      • Fees for Non-CME Services: Vertex, Genentech, Merck, Gilead
      • Contracted Research: Abbott, Bristol-Myers Squibb, Gilead, Genentech, Janssen, Vertex
  • External Reviewer reports the following relationship(s):
    • Craig Aronchick, MD
      • No relevant financial relationships to disclose.
  • Vindico Medical Education staff report the following relationship(s):
    • No relevant financial relationships to disclose.
  • BetterCME staff report the following relationship(s):
    • No relevant financial relationships to disclose.
  • Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.